-
2023-505946-24-00
5
2025-05-15
Primary Immunodeficiency Diseases
-
2024-511239-91-00
4
2025-05-05
Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)
-
2024-512600-19-00
5
2025-04-14
Angelman Syndrome
-
2023-508015-23-00
5
2025-04-11
Ovarian cancer recurrent
-
2024-512659-19-00
10
2025-03-31
Advanced Melanoma
-
2024-514499-42-00
5
2025-03-12
Refractory Partial Onset Epilepsy
-
2024-512126-29-00
5
2025-02-25
Generalized Myasthenia Gravis
-
2024-515702-63-00
5
2025-02-20
Moderate-to-Severe Active Thyroid Eye Disease
-
2024-511457-22-00
3
2025-01-30
Advanced Hematologic Malignancies
-
2024-513356-15-00
5
2024-12-30
Acquired Blepharoptosis
-
2024-511879-16-00
5
2024-12-12
Prurigo Nodularis
-
2023-507746-83-00
5
2024-11-27
Generalized Myasthenia Gravis
-
2023-503630-44-00
10
2024-11-20
Treatment of moderate-to-severe Atopic dermatitis
-
2024-512423-36-00
5
2024-11-20
Undifferentiated pleomorphic sarcoma
-
2023-506235-15-00
5
2024-11-07
Limited-Stage Small-Cell Lung Cancer (LS SCLC)
-
2023-508805-26-00
1
2024-10-23
patients with active brain metastases, where the primary tumour has co
-
2023-504231-41-01
10
2024-10-02
Locally advanced or metastatic urothelial cancer
-
2023-510017-26-00
1
2024-10-02
Completely Resected Stage IIB, IIC, and III Melanoma
-
2023-507129-40-00
4
2024-08-06
interstitial lung disease secondary to systemic sclerosis (SSc-ILD)
-
2023-503699-25-00
5
2024-07-15
Progressive Pulmonary Fibrosis
-
2023-503697-21-01
5
2024-06-24
Idiopathic pulmonary fibrosis
-
2023-508099-12-00
5
2024-06-20
Dermatitis atopic
-
2023-503545-67-00
5
2024-04-30
Tourette's Disorder
-
2022-501478-21-00
5
2024-03-15
Atopic Dermatitis
Eczema